The Chk2 protein kinase - PubMed (original) (raw)
Review
The Chk2 protein kinase
Jinwoo Ahn et al. DNA Repair (Amst). 2004 Aug-Sep.
Abstract
Checkpoint kinase 2 (Chk2) is a multifunctional enzyme whose functions are central to the induction of cell cycle arrest and apoptosis by DNA damage. Insight into Chk2 has derived from multiple approaches. Biochemical studies have addressed Chk2 structure, domain organization and regulation by phosphorylation. Extensive work has been done to identify factors that recognize and respond to DNA damage in order to activate Chk2. In turn a number of substrates and targets of Chk2 have been identified that play roles in the checkpoint response. The roles and regulation of Chk2 have been elucidated by studies in model genetic systems extending from worms and flies to mice and humans. The relationship of Chk2 to human cancer studies is developing rapidly with increasing evidence that Chk2 plays a role in tumor suppression.
Similar articles
- The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, Kroemer G. Castedo M, et al. Oncogene. 2004 May 27;23(25):4353-61. doi: 10.1038/sj.onc.1207573. Oncogene. 2004. PMID: 15048074 - Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.
Bahassi el M, Myer DL, McKenney RJ, Hennigan RF, Stambrook PJ. Bahassi el M, et al. Mutat Res. 2006 Apr 11;596(1-2):166-76. doi: 10.1016/j.mrfmmm.2005.12.002. Epub 2006 Feb 14. Mutat Res. 2006. PMID: 16481012 - Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.
Cai Z, Chehab NH, Pavletich NP. Cai Z, et al. Mol Cell. 2009 Sep 24;35(6):818-29. doi: 10.1016/j.molcel.2009.09.007. Mol Cell. 2009. PMID: 19782031 - CHK2 kinase--a busy messenger.
Bartek J, Falck J, Lukas J. Bartek J, et al. Nat Rev Mol Cell Biol. 2001 Dec;2(12):877-86. doi: 10.1038/35103059. Nat Rev Mol Cell Biol. 2001. PMID: 11733767 Review. - Chk1 and Chk2 kinases in checkpoint control and cancer.
Bartek J, Lukas J. Bartek J, et al. Cancer Cell. 2003 May;3(5):421-9. doi: 10.1016/s1535-6108(03)00110-7. Cancer Cell. 2003. PMID: 12781359 Review.
Cited by
- Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.
Schreurs MAC, Adank MA, Hollestelle A, de Groot R, Stommel-Jenner DJ, Van Asperen CJ, Ausems MGEM, Berger LPV, Blok MJ, van Engelen K, Hogervorst FBL, Geurts-Giele W, Gille JJP, Wevers MR, Schmidt MK, Hooning MJ. Schreurs MAC, et al. BMJ Open. 2024 Oct 9;14(10):e086688. doi: 10.1136/bmjopen-2024-086688. BMJ Open. 2024. PMID: 39384226 Free PMC article. - Potential promising of synthetic lethality in cancer research and treatment.
Karami Fath M, Najafiyan B, Morovatshoar R, Khorsandi M, Dashtizadeh A, Kiani A, Farzam F, Kazemi KS, Nabi Afjadi M. Karami Fath M, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 21. doi: 10.1007/s00210-024-03444-6. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39305329 Review. - Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status.
McClellan JC, Li JL, Gao G, Huo D. McClellan JC, et al. Breast Cancer Res. 2024 Mar 21;26(1):51. doi: 10.1186/s13058-024-01809-6. Breast Cancer Res. 2024. PMID: 38515142 Free PMC article. - Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with CHEK2 Germline Mutations.
Gąsior-Perczak D, Kowalik A, Kopczyński J, Macek P, Niemyska K, Walczyk A, Gruszczyński K, Siołek M, Dróżdż T, Kosowski M, Pałyga I, Przybycień P, Wabik O, Góźdź S, Kowalska A. Gąsior-Perczak D, et al. Cancers (Basel). 2024 Feb 17;16(4):815. doi: 10.3390/cancers16040815. Cancers (Basel). 2024. PMID: 38398207 Free PMC article. - Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs.
Du Y, Luo L, Xu X, Yang X, Yang X, Xiong S, Yu J, Liang T, Guo L. Du Y, et al. Pharmaceutics. 2023 Oct 8;15(10):2433. doi: 10.3390/pharmaceutics15102433. Pharmaceutics. 2023. PMID: 37896193 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases